CLPBF (Coloplast AS) Other Financing: $0 Mil (TTM As of Mar. 2026)


CLPBF Coloplast AS CLPBF
72 GF Score
Price $57.41
GF Value $125.62
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Coloplast AS Other Financing?

Coloplast AS CLPBF 72 Other Financing is $0 Mil as of Mar. 2026. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $125.62 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Coloplast AS's Other Financing for the three months ended in Mar. 2026 was $-0 Mil.

Coloplast AS's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

Coloplast AS Other Financing Historical Data

* Premium members only.

The historical data trend for Coloplast AS's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coloplast AS Other Financing Chart

Coloplast AS Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 69.31 -0.00 0.00 0.00

Coloplast AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00
CLPBF
72GF Score
Coloplast AS CLPBF
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coloplast AS Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0 Mil mean?
Coloplast AS (CLPBF) has a Other Financing of $0 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Coloplast AS and its competitors.
Is Coloplast AS's Other Financing too high?
Coloplast AS's current Other Financing is $0 Mil. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Other Financing compare to ISRG and BDX?
Coloplast AS's Other Financing of $0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Devices & Instruments company?
A good Other Financing depends on the Medical Devices & Instruments industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Coloplast AS and its competitors. Coloplast AS's current Other Financing is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $125.62, compared to a current price of $57.41 — trading 54.3% below its estimated fair value. The current Other Financing is $0 Mil. Coloplast AS's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current Other Financing is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coloplast AS (CLPBF) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of $57.41 is trading 54.3% below its estimated GF Value™ of $125.62. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for CLPBF:

  • Other Financing: $0 Mil
  • GF Value™: $125.62 vs. price of $57.41 (54.3% below fair value)
  • GF Score™: 72/100 with 7 warning signs

No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coloplast AS Business Description

Address Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score

Get the complete analysis for CLPBF

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$57.41
Price
$125.62
GF Value